QuickView for ceramide phosphoethanolamine biosynthetic process (biogroup)

1. Mononuclear cells from bone marrow and peripheral blood of AML patients before decitabine therapy
2. Breast cancer MDA-MB-231 cells with PIN1 knockdown or treated with covalent PIN1 inhibitor KPT-6566
3. Hela cells with siRae1 and siNT infected with VSV or mock infected
4. Neuroendocrine colon tumor and small intestinal carcinoid cells infected with Chlamydia trachomatis
5. Quadriceps expression profiles in MNST nulls and in WT treated with a soluble ActIIB receptor

There were no matches for ceramide phosphoethanolamine biosynthetic process

There were no clinical trials for ceramide phosphoethanolamine biosynthetic process